Immunotoxicology
Understanding potential effects on the immune system is critical for ensuring the safety of pharmaceutical and non-pharmaceutical products. Our immuno toxicology services are designed to complement standard toxicity studies, providing deeper insights into immune modulation, functional responses, and potential immunological risks throughout product development.
We offer a comprehensive range of immunological endpoints conducted concomitantly with routine toxicity studies. These include immune cell phenotyping using flow cytometry to assess changes in key immune cell populations, as well as natural killer (NK) cell assays to evaluate innate immune function. In addition, we perform serum immunoglobulin isotyping (IgG, IgA, IgM, and IgE) and cytokine profiling, including Th1/Th2 responses, to characterise systemic immune status and immune balance.
Our capabilities extend to the detection of serum autoantibodies and the design of customised functional immunoassays tailored to specific study objectives or regulatory expectations. By integrating these immune assessments with standard toxicology endpoints, we help generate a holistic understanding of immune safety, supporting informed decision-making across pharmaceutical, biotechnology, and non-pharmaceutical development programs.
Key Services Include
- Immune cell phenotyping by flow cytometry
- Natural Killer (NK) cell assays
- Serum immunoglobulin (IgG, IgA, IgM, IgE) isotyping
- Serum autoantibodies
- Customised functional assays
Scientific Partnership
Partnering for Scientific Excellence
Adgyl Lifesciences is committed to ensure
Scientifically rigorous, reproducible and timely study execution.
High‑quality data generation aligned with scientific & regulatory requirements
Seamless end‑to‑end support spanning study design, execution, and data interpretation.
Connect with our expert team today to discuss how we can support your immunotoxicology studies.
what people ask
Frequently Asked Questions
Can these immune assessments be conducted alongside standard toxicity studies?
Yes. All immunological evaluations are designed to be conducted concomitantly with standard toxicity studies, allowing immune-related endpoints to be interpreted in the context of systemic exposure, target organ effects, and overall toxicological findings.
Are these studies customisable based on regulatory or project needs?
Absolutely. Immune endpoints and functional assays can be customised to meet specific regulatory expectations, therapeutic classes, or product-specific risk profiles, ensuring relevance and scientific robustness.
Do you support exploratory immune screening studies?
Yes. In addition to studies conducted alongside regulatory toxicity programs, we also offer non‑GLP exploratory immune screening studies to support early candidate selection and risk assessment.
Are customised assays available for novel or first‑in‑class compounds?
Absolutely. We work closely with clients to develop and implement customised functional immune assays tailored to novel mechanisms, targets, or emerging therapeutic modalities.
Can these services support decision-making before advancing to long-term studies?
Yes. Early immune assessments provide critical data that support go/no‑go decisions, dose selection, and study design optimisation before advancing to longer-duration or higher-investment studies.
